Filing Overview
Registrant: Blue Water Biotech, Inc. (the filing text does not identify Onconetix, Inc. as the registrant).
Form 8-K date: September 18, 2023; signed September 22, 2023. The report concerns a Nasdaq continued-listing deficiency and does not cover a financial reporting period.
Business Context and Financial Metrics
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics. It reports a securities-listing matter rather than quarterly or annual financial results.
Material Change
On September 18, 2023, Nasdaq notified the company that its common stock had closed below the $1.00 minimum bid price for 30 consecutive business days, resulting in noncompliance with Nasdaq Listing Rule 5550(a)(2).
- The notice had no immediate effect on the Nasdaq Capital Market listing.
- The company received 180 calendar days, until March 16, 2024, to regain compliance.
- Compliance requires a closing bid price of at least $1.00 for at least 10 consecutive business days, subject to Nasdaq’s discretion to extend the measurement period.
Outlook, Risks, and Contingencies
Management stated that it intends to monitor the stock’s closing bid price and consider available options to remedy the deficiency.
If compliance is not regained by March 16, 2024, the company may be eligible for an additional 180-day compliance period if it satisfies applicable Nasdaq requirements and provides written notice of its intention to cure the deficiency, potentially through a reverse stock split. If the company is not eligible or cannot cure the deficiency, Nasdaq may issue a delisting notice.
The company may request a hearing before the Nasdaq Hearings Panel, which could stay suspension or delisting proceedings while the hearing process is pending. The filing states that there is no assurance the company will receive an additional compliance period, successfully appeal a delisting determination, regain compliance, or maintain compliance with other Nasdaq requirements.
Investor Verification Items
- Confirm the registrant identity, because the supplied filing names Blue Water Biotech, Inc., while the request metadata names Onconetix, Inc.
- Verify whether the company regained compliance by March 16, 2024 or obtained an additional compliance period.
- Check for subsequent Nasdaq notices, reverse-stock-split actions, hearings, or delisting proceedings.
- Review later filings for updated listing status, capital structure changes, and any related financing or liquidity effects.